Top

Published in:

Open Access 01-12-2018 | Letter to the Editor

It is time to move forward into the era of Theranostics

Authors: Hojjat Ahmadzadehfar, Markus Essler

Published in: EJNMMI Research | Issue 1/2018

Abstract

Radionuclide therapy, which until 15 years ago included only a few approved therapies, is gaining importance in the treatment of various malignancies. The future of oncology will not be limited to surgery, chemo-, antibody therapies or external radiation; it will include targeted therapy with radionuclides, which will become the standard of care for a variety of malignant diseases in combination or as an alternative to other therapies. Therefore there is a need to train Nuclear Oncologists, who are able to approach oncological diseases, promote development of radiopharmacy, understand the biology of radionuclide treatment, apply radionuclide treatments and be able to use molecular imaging such as PET/CT and SPECT/CT for treatment planning and dosimetry.

Braat AJ, Smits ML, Braat MN, van den Hoven AF, Prince JF, de Jong HW, et al. (9)(0)Y hepatic radioembolization: an update on current practice and recent developments. J Nucl Med. 2015;56:1079–87. https://doi.org/10.2967/jnumed.115.157446.CrossRefPubMed

Yordanova A, Mayer K, Brossart P, Gonzalez-Carmona MA, Strassburg CP, Essler M, et al. Safety of multiple repeated cycles of 177Lu-octreotate in patients with recurrent neuroendocrine tumour. Eur J Nucl Med Mol Imaging. 2017;44:1207–14. https://doi.org/10.1007/s00259-017-3652-1.CrossRefPubMed

Bodei L, Cremonesi M, Grana CM, Chinol M, Baio SM, Severi S, et al. Yttrium-labelled peptides for therapy of NET. Eur J Nucl Med Mol Imaging. 2012;39(Suppl 1):S93–102. https://doi.org/10.1007/s00259-011-2002-y.CrossRefPubMed

Tennvall J, Fischer M, Bischof Delaloye A, Bombardieri E, Bodei L, Giammarile F, et al. EANM procedure guideline for radio-immunotherapy for B-cell lymphoma with 90Y-radiolabelled ibritumomab tiuxetan (Zevalin). Eur J Nucl Med Mol Imaging. 2007;34:616–22. https://doi.org/10.1007/s00259-007-0372-y.CrossRefPubMed

Liepe K, Kotzerke J. Internal radiotherapy of painful bone metastases. Methods. 2011;55:258–70. https://doi.org/10.1016/j.ymeth.2011.07.001.CrossRefPubMed

Ahmadzadehfar H, Rahbar K, Kurpig S, Bogemann M, Claesener M, Eppard E, et al. Early side effects and first results of radioligand therapy with (177)Lu-DKFZ-617 PSMA of castrate-resistant metastatic prostate cancer: a two-centre study. EJNMMI Res. 2015;5:114. https://doi.org/10.1186/s13550-015-0114-2.PubMed

Ahmadzadehfar H, Wegen S, Yordanova A, Fimmers R, Kurpig S, Eppard E, et al. Overall survival and response pattern of castration-resistant metastatic prostate cancer to multiple cycles of radioligand therapy using [177Lu]Lu-PSMA-617. Eur J Nucl Med Mol Imaging. 2017;44:1448–54. https://doi.org/10.1007/s00259-017-3716-2.CrossRefPubMed

Ahmadzadehfar H, Zimbelmann S, Yordanova A, Fimmers R, Kurpig S, Eppard E, et al. Radioligand therapy of metastatic prostate cancer using 177Lu-PSMA-617 after radiation exposure to 223Ra-dichloride. Oncotarget. 2017;8:55567–74. https://doi.org/10.18632/oncotarget.15698.PubMedPubMedCentral

Yordanova A, Becker A, Eppard E, Kurpig S, Fisang C, Feldmann G, et al. The impact of repeated cycles of radioligand therapy using [177Lu]Lu-PSMA-617 on renal function in patients with hormone refractory metastatic prostate cancer. Eur J Nucl Med Mol Imaging. 2017;44(9):1473. https://doi.org/10.1007/s00259-017-3681-9.CrossRefPubMed

10.

Rahbar K, Ahmadzadehfar H, Kratochwil C, Haberkorn U, Schafers M, Essler M, et al. German multicenter study investigating 177Lu-PSMA-617 radioligand therapy in advanced prostate cancer patients. J Nucl Med. 2017;58:85–90. https://doi.org/10.2967/jnumed.116.183194.CrossRefPubMed

11.

Mier W, Kratochwil C, Hassel JC, Giesel FL, Beijer B, Babich JW, et al. Radiopharmaceutical therapy of patients with metastasized melanoma with the melanin-binding benzamide 131I-BA52. J Nucl Med. 2014;55:9–14. https://doi.org/10.2967/jnumed.112.112789.CrossRefPubMed

12.

Sultana A, Shore S, Raraty MG, Vinjamuri S, Evans JE, Smith CT, et al. Randomised phase I/II trial assessing the safety and efficacy of radiolabelled anti-carcinoembryonic antigen I(131) KAb201 antibodies given intra-arterially or intravenously in patients with unresectable pancreatic adenocarcinoma. BMC Cancer. 2009;9:66. https://doi.org/10.1186/1471-2407-9-66.CrossRefPubMedPubMedCentral

13.

Sahlmann CO, Homayounfar K, Niessner M, Dyczkowski J, Conradi LC, Braulke F, et al. Repeated adjuvant anti-CEA radioimmunotherapy after resection of colorectal liver metastases: safety, feasibility, and long-term efficacy results of a prospective phase 2 study. Cancer. 2017;123:638–49. https://doi.org/10.1002/cncr.30390.CrossRefPubMed

14.

Hagemann UB, Wickstroem K, Wang E, Shea AO, Sponheim K, Karlsson J, et al. In vitro and in vivo efficacy of a novel CD33-targeted thorium-227 conjugate for the treatment of acute myeloid Leukemia. Mol Cancer Ther. 2016;15:2422–31. https://doi.org/10.1158/1535-7163.MCT-16-0251.CrossRefPubMed

15.

Lapa C, Herrmann K, Schirbel A, Hanscheid H, Luckerath K, Schottelius M, et al. CXCR4-directed endoradiotherapy induces high response rates in extramedullary relapsed multiple myeloma. Theranostics. 2017;7:1589–97. https://doi.org/10.7150/thno.19050.CrossRefPubMedPubMedCentral

16.

DeVita VT, Lawrence TS, Rosenberg SA. Devita, Hellman, and Rosenberg’s cancer : principles & practice of oncology. 10th ed. Philadelphia: Wolters Kluwer; 2015.

Title: It is time to move forward into the era of Theranostics
Authors: Hojjat Ahmadzadehfar
Markus Essler
Publication date: 01-12-2018
Publisher: Springer Berlin Heidelberg
Published in: EJNMMI Research / Issue 1/2018
Electronic ISSN: 2191-219X
DOI: https://doi.org/10.1186/s13550-018-0364-x

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

It is time to move forward into the era of Theranostics

Abstract

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 1/2018

Positron emission tomography-magnetic resonance imaging (PET-MRI) for response assessment after radiation therapy of cervical carcinoma: a pilot study

[11C]SCH23390 binding to the D1-dopamine receptor in the human brain—a comparison of manual and automated methods for image analysis

Impact of time-of-flight PET on quantification accuracy and lesion detection in simultaneous 18F-choline PET/MRI for prostate cancer

In vivo confirmation of altered hepatic glucose metabolism in patients with liver fibrosis/cirrhosis by 18F-FDG PET/CT

Optimization of temporal sampling for 18F-choline uptake quantification in prostate cancer assessment

Correlation of neuropsychological and metabolic changes after epilepsy surgery in patients with left mesial temporal lobe epilepsy with hippocampal sclerosis